Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia.

Ito S, Potnis KC, Ng DQ, Patel KK, Sra M, Shallis RM, Podoltsev NA, Kewan T, Stempel JM, Mendez L, Huntington SF, Stahl M, Zeidan AM, Bewersdorf JP, Goshua G

Open source

DOI: 10.1016/j.brci.2026.100076
Published: 2026 Jun
Container: Blood red cells & iron
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.brci.2026.100076,
  title = {Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia.},
  author = {Ito S and Potnis KC and Ng DQ and Patel KK and Sra M and Shallis RM and Podoltsev NA and Kewan T and Stempel JM and Mendez L and Huntington SF and Stahl M and Zeidan AM and Bewersdorf JP and Goshua G},
  year = {2026},
  journal = {Blood red cells \& iron},
  doi = {10.1016/j.brci.2026.100076},
  url = {https://doi.org/10.1016/j.brci.2026.100076}
}

RIS

TY  - JOUR
TI  - Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia.
AU  - Ito S
AU  - Potnis KC
AU  - Ng DQ
AU  - Patel KK
AU  - Sra M
AU  - Shallis RM
AU  - Podoltsev NA
AU  - Kewan T
AU  - Stempel JM
AU  - Mendez L
AU  - Huntington SF
AU  - Stahl M
AU  - Zeidan AM
AU  - Bewersdorf JP
AU  - Goshua G
PY  - 2026
JO  - Blood red cells & iron
DO  - 10.1016/j.brci.2026.100076
UR  - https://doi.org/10.1016/j.brci.2026.100076
ER  -

APA

S, I., KC, P., DQ, N., KK, P., M, S., RM, S., NA, P., T, K., JM, S., L, M., SF, H., M, S., AM, Z., JP, B., & G, G. (2026). Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia.. Blood red cells & iron. https://doi.org/10.1016/j.brci.2026.100076

Source records

pubmed · retrieved 2026-09-26T11:32:18.172Z